narlaprevir
Small moleculeexperimental
Narlaprevir, is an inhibitor of NS3/4A serine protease, intended for the treatment of chronic hepatitis C caused by genotype 1 virus in combination with other antiviral drugs. — Wikipedia
Clinical trial activity
8 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
4
Phase 3
2
Phase 4
0
Earliest trial started Feb 1, 2007 (NCT00689390)
Timeline
Indications
Mechanism of action
A3EZI9 inhibitor
Hepatitis C virus serine protease, NS3/NS4A inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCCC[C@H](NC(=O)[C@@H]1[C@@H]2[C@H](CN1C(=O)[C@@H](NC(=O)NC1(CS(=O)(=O)C(C)(C)C)CCCCC1)C(C)(C)C)C2(C)C)C(=O)C(=O)NC1CC1- Mol. weight
- 707.98 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaNarlaprevir ↗
- ChEMBLCHEMBL1255891 ↗
Also known as
- narlaprevir
- narlaprevir
- narlaprevir
- narlaprevir
- sch900518
- sch900518
- sch 900518
- sch 900518
- sch 900518
- sch-900518
- sch-900518
- sch-900518
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04246723 | Phase 2 | May 6, 2019 | Almedis, ChromSystemsLab, EFiS, R-Pharm |
| NCT03485846 | Phase 2 | Nov 27, 2017 | Almedis, R-Pharm |
| NCT03537404 | Phase 1 | Apr 24, 2017 | Almedis, R-Pharm |
| NCT03833362 | Phase 3 | May 7, 2014 | R-Pharm |
| NCT03832426 | Phase 1 | Nov 8, 2013 | Ascent Pharmahealth, R-Pharm |
| NCT00797745 | Phase 2 | Nov 1, 2008 | Merck |
| NCT01081158 | Phase 1 | Jul 1, 2007 | Merck |
| NCT00689390 | Phase 2/Phase 3 (Phase 3) | Feb 1, 2007 | Merck |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| R-Pharm | For profit | 5 | 5 | 3 | 2013 |
| Almedis | For profit | 3 | 0 | 2 | 2017 |
| Merck | For profit | 3 | 3 | 3 | 2007 |
| Ascent Pharmahealth | For profit | 1 | 0 | 1 | 2013 |
| ChromSystemsLab | For profit | 1 | 0 | 1 | 2019 |
| EFiS | Academic/Hospital | 1 | 0 | 1 | 2019 |
6 organizations
Page 1 / 1